Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Compass Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 34 | 1 | 38 | +5 |
| Shares | 61.9M | 14.9K | 63.9M | +1.98M (+3.2%) |
| Value | $163.9M | $40.0K | $145.6M | −$18.3M (−11.1%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Compass Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Eventide Asset Management, LLC | 1,100,399 | $2.51M | 0.05% |
| Silverarc Capital Management, LLC | 262,090 | $598.0K | 0.25% |
| Northern Trust Corp | 87,367 | $199.0K | 0.00% |
| Charles Schwab Investment Management Inc | 31,736 | $73.0K | 0.00% |
| Bank of New York Mellon Corp | 24,251 | $55.0K | 0.00% |
| Susquehanna International Group, LLP | 19,738 | $45.0K | 0.00% |
| Jane Street Group, LLC | 14,265 | $33.0K | 0.00% |
| Wells Fargo & Company | 457 | $1.00K | 0.00% |
| Barclays PLC | 374 | $1.00K | 0.00% |
Sold out (4)
Institutions that held Compass Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Consonance Capital Management LP | 1,603,789 | $4.22M |
| CM Management, LLC | 30,000 | $80.0K |
| Mascoma Wealth Management LLC | 15,682 | $42.0K |
| Charter Oak Capital Management, LLC | 1,483 | $4.00K |
Not filed for Q3 2022 yet (1)
Institutions that held Compass Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| B. Riley Wealth Management, Inc. | 14,918 | $40.0K |